Omics experimental methods are becoming critical in many areas of drug discovery, to allow the development of next generation, innovative therapeutics.
Degenerative brain disorders affect more than 45 million people worldwide. These diseases often strike older adults and are characterized by progressive deterioration of nerve cells, eventually leading to cell death. Through human and animal studies researchers are developing new diagnosis and treatment of these disorders, with the goal of slowing or stopping their progression. Finding the cause of each degenerative disorder is important in identifying treatments.
Rodin Therapeutics is a venture-backed biotechnology company developing best-in-class therapeutics for neurological disorders by harnessing the power of targeting genes that improve impaired synaptic function. Rodin’s approach is to improve neuronal synaptic resilience via the selective inhibition of histone de-acetylase (HDAC) complexes. Evidence supports that the modulation of selective gene regulatory processes can restore synaptic plasticity and cognitive function deficits present in degenerative brain diseases, including Alzheimer’s disease and Parkinson’s disease dementia.
Scientists at Rodin study changes in gene expression in brain regions of wild-type and Alzheimer’s transgenic animals after treatment with Rodin compounds. Treatment up-regulates the expression of selected genes associated with learning and memory; QOE was chosen to analyze NanoString and other Omics data used to characterize the response to treatment with Rodin’s compounds. Omics Explorer from Qlucore was selected as the best blend of power and ease-of-use that Rodin scientists could use for analysis of this Omics data.